Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01482143 · ClinicalTrials.gov registry record · Phase 1
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)
A Phase 1 study of Fragile X Syndrome, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 4
- Study locations
NCT01482143: Completed Phase 1 study of Fragile X Syndrome, sponsored by Novartis Pharmaceuticals.
NCT01482143 is a Phase 1 study of Fragile X Syndrome that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 21 participants, below the 100-participant average among 16 other Fragile X Syndrome trials with a reported enrollment target (79% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01482143, a Phase 1 study of Fragile X Syndrome, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 4
- Study locations
Study Summary
The aim of this study is to characterize the pharmacokinetics and safety/tolerability of AFQ056 in children with Fragile X Syndrome(FXS)
Conditions Studied
Interventions
- DRUG AFQ056
Study Locations (4)
California
- Novartis Investigative Site - Sacramento
Illinois
- Novartis Investigative Site - Chicago
Tennessee
- Novartis Investigative Site - Nashville
Catalonia
- Novartis Investigative Site - Sant Cugat del Vallès
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
What the finished NCT01482143 record still lists
NCT01482143 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 100-participant average among 16 other Fragile X Syndrome trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Fragile X Syndrome appearing as the primary indexed condition, and to 1 intervention - of which AFQ056 is the first listed.
NCT01482143 reports a single indexed study location in California, Illinois, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01482143 about?
NCT01482143 is a clinical study titled "Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)". The aim of this study is to characterize the pharmacokinetics and safety/tolerability of AFQ056 in children with Fragile X Syndrome(FXS)
What is the current status of trial NCT01482143?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2012-03. Estimated completion is 2013-10.
What conditions does trial NCT01482143 study?
This clinical trial studies the following conditions: Fragile X Syndrome.
What interventions are being tested in trial NCT01482143?
The interventions under investigation include: AFQ056 (DRUG).
Who is sponsoring clinical trial NCT01482143?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01482143 being conducted?
This trial has 4 study locations across California, Illinois, Tennessee, Catalonia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fragile X Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01482143's enrollment target sits among peer trials
21 14th of 16 higher than 3 of 16 other Fragile X Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fragile X Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Initial Study of AZD7325 in Adults With Fragile X Syndrome
COMPLETED · Phase 1
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant
RECRUITING · NA
-
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
RECRUITING · NA
-
Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG-Preschool Age
RECRUITING · NA
-
Speech-in-noise Perception in Autism and Fragile X
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia